论文部分内容阅读
欧盟有关机构近日批准,正在合并中的葛兰素一史克集团生产出治疗艾滋病的新药“三泽维尔”(Trizivir)抗毒片。葛兰素一史克集团声称,这种新药在一个药片中包含了三种抗艾滋病病毒(HIV)成分,是抗艾滋病药物的首创。这个制药集团说,与目前市场上已经有的治疗艾滋病病毒感染的药物相比“三泽维尔”抗毒片的好处尤其在于服用方便;每日二次,每次一片,不需要对饮食作任何限制。据葛兰素一史克集团介绍说,这种新药片将帮助受到艾滋病病毒感染的人更容易在服药时不影响每日的正常生活。此外,这种新药与葛兰素一史克集团其它艾滋病类药物具有互补的疗效。据悉,“三泽维尔”已经在2000年11月得到美国有关当局的生产许可。而墨西哥、瑞士、智利加纳和马拉维等国也已经批准了Trizivir作为治疗艾滋病病毒的药物。
Relevant agencies of the European Union recently approved the ongoing merger of GlaxoSmithKline to produce a new drug for AIDS treatment “Trizivir” anti-drug tablets. GlaxoSmithKline claims the new drug contains three anti-HIV components in one tablet and is the first of its kind to fight AIDS. The pharmaceutical group said the benefits of the “San Xavier” anti-drug tablets are more convenient than those currently available on the market for the treatment of HIV infections; twice daily, one tablet at a time, without the need for diet Make any restrictions. According to GlaxoSmithKline, the new pill will make it easier for those infected with HIV to take daily medications without affecting their daily routine. In addition, the new drug has complementary effects with other GSGs of GSK. It is reported that “San Xavier ” in November 2000 has been the production license of the relevant U.S. authorities. Countries such as Mexico, Switzerland, Ghana, Chile and Malawi have also ratified Trizivir as a treatment for HIV.